Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis : Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 194(2018) vom: 01. Sept., Seite 9-18
1. Verfasser: Zhang, Yujuan (VerfasserIn)
Weitere Verfasser: Gupta, Saloni, Ilstad-Minnihan, Alexandra, Ayyangar, Sashi, Hay, Arielle D, Pascual, Virginia, Ilowite, Norman T, Macaubas, Claudia, Mellins, Elizabeth D
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Juvenile arthritis Monocytes;cytokine Interleukin-1 Interleukin-1beta Recombinant Fusion Proteins STAT1 Transcription Factor Suppressor of Cytokine Signaling 1 Protein mehr... rilonacept 8K80YB5GMG
Beschreibung
Zusammenfassung:Copyright © 2018 Elsevier Inc. All rights reserved.
Systemic juvenile idiopathic arthritis (sJIA) is a childhood rheumatic disease of unknown origin. Dysregulated innate immunity is implicated in disease pathology. We investigated if IL-1 inhibition affects circulating cytokines and monocyte gene expression. CD14+ monocytes from patients in the RAPPORT trial were analyzed by RT-PCR for expression of IL1B and transcription factors associated with monocyte activation. Serum IL-1ra decreased with treatment, and IL-18BP transiently increased. Serum levels of IL-1β, IL-6, IL-10 and IL-18 were unchanged. IRF5 and STAT6 were decreased, and PPARG was increased, independent of clinical response, and may represent a skew toward a PPARG-driven M2-like phenotype. IL1B expression was decreased in early clinical responders. A transient increase in STAT1, and a decrease in SOCS1 preceded the reduction in IL1B in early clinical responders. Changes in IL1B/STAT1/SOCS1 could be associated with crosstalk between IL-1 and IFN pathways in sJIA. These transcriptional changes might be useful as drug response biomarkers
Beschreibung:Date Completed 14.08.2019
Date Revised 10.05.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.06.005